Related Experiment Videos

Indications for therapy for fungemia in postoperative patients

Insights

Fungal infections (fungemia) in surgical patients, often linked to abdominal issues, are deadly if untreated. Early amphotericin B therapy significantly improves survival rates for these serious Candida infections.

Area of Science:

  • Infectious Diseases
  • Surgical Infections
  • Mycology

Background:

  • Fungemia is a serious complication in surgical patients, particularly those with intra-abdominal infections.
  • Candida species are frequently involved in polymicrobial infections within the abdominal cavity.

Purpose of the Study:

  • To determine the clinical settings of fungemia in surgical patients.
  • To define indications for systemic antifungal therapy.
  • To evaluate the impact of therapy on mortality.

Main Methods:

  • Retrospective review of clinical courses of 63 surgical patients with fungemia.
  • Analysis of infection sources, causative organisms, and treatment outcomes.
  • Autopsy findings in 20 cases to identify visceral microabscesses and fungal sources.

Main Results:

  • Fifty-one patients (81%) developed fungemia as a late complication of intraperitoneal infection.
  • Candida was part of polymicrobial flora in 70% of cases.
  • Untreated fungemia had an 83% mortality rate; no untreated patients survived fungemia >1 day.
  • Amphotericin B therapy ( >3 mg/kg) improved survival to 67% (10/15).
  • Autopsies revealed visceral Candida microabscesses in 7/20 patients, with GI tract and intra-abdominal abscesses as common sources.

Conclusions:

  • Candida plays a significant role in polymicrobial intra-abdominal infections.
  • Systemic therapy with amphotericin B is recommended for surgical patients with intraperitoneal infections experiencing fungemia.
  • Prompt diagnosis and treatment are crucial for improving outcomes in fungemia.

Related Concept Videos